Truist lowered the firm’s price target on Neurocrine (NBIX) to $169 from $172 and keeps a Buy rating on the shares. The firm updated its model, but tells investors in a research note that the fundamental views remain intact from 2025.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine downgraded to Equal Weight from Overweight at Morgan Stanley
- RBC Capital would be a buyer of Neurocrine on weakness following competitor data
- Neurocrine Biosciences: Ingrezza-Driven Strength and Risk-Balanced Pipeline Support Buy Rating Despite Valbenazine Setback
- Buy Rating Reaffirmed on Neurocrine: Limited Impact from Trial Setback, Strength in Core Execution and Deep Pipeline Upside
- Neurocrine says Phase 3 KINECT-DCP study of valbenazine did not meet endpoints